How Trump's Psychedelics Executive Order Could Unlock Stalled Cannabis Reform

Why It Matters

The order signals a federal shift toward evidence‑based, physician‑led drug development, potentially unlocking investment and research momentum for both psychedelics and cannabis. By establishing a research‑centric model, it may pressure agencies to move cannabis out of Schedule I, reshaping the alternative‑medicine market.

Key Takeaways

• Trump order speeds psychedelic clinical trials and Right‑to‑Try access
• Scheduling unchanged; focus remains on research acceleration
• AtaiBeckley shares jumped ~25% after order announcement
• Experts view psychedelic pathway as template for cannabis rescheduling
• Federal inter‑agency review continues to delay cannabis schedule change

Pulse Analysis

The White House’s new psychedelics executive order marks a rare moment of bipartisan support for a controversial class of substances. By directing the FDA and other agencies to expand clinical trials and broaden Right‑to‑Try pathways, the order creates a structured, data‑driven route for drugs like psilocybin, MDMA and ibogaine. Although the order does not alter scheduling, it underscores a strategic pivot toward a medical‑first framework, echoing President Trump’s earlier, unfinished push to reschedule cannabis. This regulatory nuance is crucial for investors and policymakers watching the evolving landscape of plant‑based therapeutics.

Market reaction was immediate. Shares of AtaiBeckley, a leading psychedelic biotech, jumped roughly 25% after the announcement, while smaller peers such as Compass Pathways, Definium Therapeutics and Cybin also saw notable gains. The rally reflects investor confidence that a clearer research pathway will reduce regulatory uncertainty and accelerate product pipelines. In contrast, cannabis remains trapped in a Schedule I classification, despite a multibillion‑dollar adult‑use market across states. The psychedelic order’s emphasis on rigorous science and physician‑led protocols offers a potential playbook for cannabis advocates seeking to demonstrate safety and efficacy to federal regulators.

Looking ahead, the order could catalyze a broader policy shift. By establishing a precedent for evidence‑based, patient‑centric drug development, it may pressure the DEA and HHS to prioritize cannabis rescheduling, especially as the two sectors share overlapping research infrastructure and advocacy coalitions. States that have already embraced regulated psychedelic access, like Colorado, may serve as testing grounds for integrated plant‑medicine frameworks. For the industry, the next critical phase will be translating accelerated research into approved therapies, which could unlock substantial capital flows and reshape the alternative‑medicine market in the United States.